Logo image of XPEV

XPENG INC - ADR (XPEV) Stock Fundamental Analysis

USA - New York Stock Exchange - NYSE:XPEV - US98422D1054 - ADR

20.52 USD
+0.52 (+2.6%)
Last: 12/8/2025, 8:04:00 PM
19.94 USD
-0.58 (-2.83%)
Pre-Market: 12/9/2025, 8:49:42 AM
Fundamental Rating

4

Overall XPEV gets a fundamental rating of 4 out of 10. We evaluated XPEV against 36 industry peers in the Automobiles industry. The financial health of XPEV is average, but there are quite some concerns on its profitability. XPEV is showing excellent growth while it is valued at reasonable prices. Keep and eye on this one!


Dividend Valuation Growth Profitability Health

2

1. Profitability

1.1 Basic Checks

XPEV had negative earnings in the past year.
In the past year XPEV had a positive cash flow from operations.
XPEV had negative earnings in each of the past 5 years.
In the past 5 years XPEV reported 4 times negative operating cash flow.
XPEV Yearly Net Income VS EBIT VS OCF VS FCFXPEV Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2018 2019 2020 2021 2022 2023 2024 0 -2B -4B -6B -8B -10B

1.2 Ratios

XPEV's Return On Assets of -4.63% is fine compared to the rest of the industry. XPEV outperforms 69.44% of its industry peers.
XPEV's Return On Equity of -14.11% is fine compared to the rest of the industry. XPEV outperforms 66.67% of its industry peers.
Industry RankSector Rank
ROA -4.63%
ROE -14.11%
ROIC N/A
ROA(3y)-10.7%
ROA(5y)-10.09%
ROE(3y)-23.94%
ROE(5y)-19.52%
ROIC(3y)N/A
ROIC(5y)N/A
XPEV Yearly ROA, ROE, ROICXPEV Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2018 2019 2020 2021 2022 2023 2024 -50 -100 -150

1.3 Margins

Looking at the Gross Margin, with a value of 16.36%, XPEV is in the better half of the industry, outperforming 66.67% of the companies in the same industry.
XPEV's Gross Margin has improved in the last couple of years.
XPEV does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 16.36%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y8.06%
GM growth 5YN/A
XPEV Yearly Profit, Operating, Gross MarginsXPEV Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2018 2019 2020 2021 2022 2023 2024 0 -5K -10K -15K -20K

4

2. Health

2.1 Basic Checks

XPEV does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for XPEV has been increased compared to 1 year ago.
The number of shares outstanding for XPEV has been increased compared to 5 years ago.
XPEV has a worse debt/assets ratio than last year.
XPEV Yearly Shares OutstandingXPEV Yearly Shares OutstandingYearly Shares Outstanding 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M 800M
XPEV Yearly Total Debt VS Total AssetsXPEV Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2018 2019 2020 2021 2022 2023 2024 20B 40B 60B 80B

2.2 Solvency

Based on the Altman-Z score of 1.25, we must say that XPEV is in the distress zone and has some risk of bankruptcy.
Looking at the Altman-Z score, with a value of 1.25, XPEV is in the better half of the industry, outperforming 63.89% of the companies in the same industry.
The Debt to FCF ratio of XPEV is 2.65, which is a good value as it means it would take XPEV, 2.65 years of fcf income to pay off all of its debts.
With an excellent Debt to FCF ratio value of 2.65, XPEV belongs to the best of the industry, outperforming 86.11% of the companies in the same industry.
XPEV has a Debt/Equity ratio of 0.78. This is a neutral value indicating XPEV is somewhat dependend on debt financing.
The Debt to Equity ratio of XPEV (0.78) is comparable to the rest of the industry.
Industry RankSector Rank
Debt/Equity 0.78
Debt/FCF 2.65
Altman-Z 1.25
ROIC/WACCN/A
WACC7.05%
XPEV Yearly LT Debt VS Equity VS FCFXPEV Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2018 2019 2020 2021 2022 2023 2024 0 10B -10B 20B 30B 40B

2.3 Liquidity

A Current Ratio of 1.14 indicates that XPEV should not have too much problems paying its short term obligations.
XPEV has a Current ratio of 1.14. This is comparable to the rest of the industry: XPEV outperforms 44.44% of its industry peers.
XPEV has a Quick Ratio of 1.00. This is a normal value and indicates that XPEV is financially healthy and should not expect problems in meeting its short term obligations.
XPEV's Quick ratio of 1.00 is fine compared to the rest of the industry. XPEV outperforms 61.11% of its industry peers.
Industry RankSector Rank
Current Ratio 1.14
Quick Ratio 1
XPEV Yearly Current Assets VS Current LiabilitesXPEV Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2018 2019 2020 2021 2022 2023 2024 10B 20B 30B 40B 50B

7

3. Growth

3.1 Past

XPEV shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 51.77%, which is quite impressive.
The Revenue has grown by 86.64% in the past year. This is a very strong growth!
Measured over the past years, XPEV shows a very strong growth in Revenue. The Revenue has been growing by 77.47% on average per year.
EPS 1Y (TTM)51.77%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%78.95%
Revenue 1Y (TTM)86.64%
Revenue growth 3Y24.87%
Revenue growth 5Y77.47%
Sales Q2Q%101.76%

3.2 Future

XPEV is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 23.29% yearly.
Based on estimates for the next years, XPEV will show a very strong growth in Revenue. The Revenue will grow by 30.94% on average per year.
EPS Next Y77.37%
EPS Next 2Y51.44%
EPS Next 3Y37.72%
EPS Next 5Y23.29%
Revenue Next Year91.99%
Revenue Next 2Y63.27%
Revenue Next 3Y46.49%
Revenue Next 5Y30.94%

3.3 Evolution

Although the future Revenue growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
XPEV Yearly Revenue VS EstimatesXPEV Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 50B 100B 150B 200B
XPEV Yearly EPS VS EstimatesXPEV Yearly EPS VS EstimatesYearly EPS VS Estimates 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 0 5 -5 -10

4

4. Valuation

4.1 Price/Earnings Ratio

XPEV reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
XPEV is valuated quite expensively with a Price/Forward Earnings ratio of 80.89.
Based on the Price/Forward Earnings ratio, XPEV is valued a bit cheaper than 66.67% of the companies in the same industry.
XPEV is valuated expensively when we compare the Price/Forward Earnings ratio to 23.56, which is the current average of the S&P500 Index.
Industry RankSector Rank
PE N/A
Fwd PE 80.89
XPEV Price Earnings VS Forward Price EarningsXPEV Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 -20 40 -40 60 80

4.2 Price Multiples

Based on the Price/Free Cash Flow ratio, XPEV is valued cheaper than 88.89% of the companies in the same industry.
Industry RankSector Rank
P/FCF 13.52
EV/EBITDA N/A
XPEV Per share dataXPEV EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 4 6 8

4.3 Compensation for Growth

The PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a correct valuation of the company.
XPEV's earnings are expected to grow with 37.72% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y51.44%
EPS Next 3Y37.72%

0

5. Dividend

5.1 Amount

XPEV does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

XPENG INC - ADR

NYSE:XPEV (12/8/2025, 8:04:00 PM)

Premarket: 19.94 -0.58 (-2.83%)

20.52

+0.52 (+2.6%)

Chartmill FA Rating
GICS IndustryGroupAutomobiles & Components
GICS IndustryAutomobiles
Earnings (Last)11-17 2025-11-17/bmo
Earnings (Next)03-16 2026-03-16/amc
Inst Owners12.74%
Inst Owner Change-4.71%
Ins Owners0.25%
Ins Owner ChangeN/A
Market Cap19.56B
Revenue(TTM)70.57B
Net Income(TTM)-4.28B
Analysts79.39
Price Target27.82 (35.58%)
Short Float %10.34%
Short Ratio3.16
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)41.32%
Min EPS beat(2)34.81%
Max EPS beat(2)47.83%
EPS beat(4)2
Avg EPS beat(4)18.11%
Min EPS beat(4)-8.69%
Max EPS beat(4)47.83%
EPS beat(8)4
Avg EPS beat(8)16.95%
EPS beat(12)4
Avg EPS beat(12)3.67%
EPS beat(16)6
Avg EPS beat(16)-1.04%
Revenue beat(2)1
Avg Revenue beat(2)-0.37%
Min Revenue beat(2)-3.26%
Max Revenue beat(2)2.52%
Revenue beat(4)2
Avg Revenue beat(4)-0.21%
Min Revenue beat(4)-3.26%
Max Revenue beat(4)2.52%
Revenue beat(8)2
Avg Revenue beat(8)-2.74%
Revenue beat(12)2
Avg Revenue beat(12)-5.64%
Revenue beat(16)5
Avg Revenue beat(16)-2.91%
PT rev (1m)7.18%
PT rev (3m)8.99%
EPS NQ rev (1m)-6.89%
EPS NQ rev (3m)-4.13%
EPS NY rev (1m)1.89%
EPS NY rev (3m)15.56%
Revenue NQ rev (1m)-0.41%
Revenue NQ rev (3m)-1.12%
Revenue NY rev (1m)-1.53%
Revenue NY rev (3m)-1.29%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE 80.89
P/S 2.29
P/FCF 13.52
P/OCF 10.62
P/B 4.56
P/tB 5.32
EV/EBITDA N/A
EPS(TTM)-0.42
EYN/A
EPS(NY)0.25
Fwd EY1.24%
FCF(TTM)1.52
FCFY7.4%
OCF(TTM)1.93
OCFY9.42%
SpS8.95
BVpS4.5
TBVpS3.86
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -4.63%
ROE -14.11%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 16.36%
FCFM 16.96%
ROA(3y)-10.7%
ROA(5y)-10.09%
ROE(3y)-23.94%
ROE(5y)-19.52%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y8.06%
GM growth 5YN/A
F-Score6
Asset Turnover0.65
Health
Industry RankSector Rank
Debt/Equity 0.78
Debt/FCF 2.65
Debt/EBITDA N/A
Cap/Depr 129.52%
Cap/Sales 4.63%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1.14
Quick Ratio 1
Altman-Z 1.25
F-Score6
WACC7.05%
ROIC/WACCN/A
Cap/Depr(3y)238.42%
Cap/Depr(5y)371.52%
Cap/Sales(3y)10.3%
Cap/Sales(5y)14.96%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)51.77%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%78.95%
EPS Next Y77.37%
EPS Next 2Y51.44%
EPS Next 3Y37.72%
EPS Next 5Y23.29%
Revenue 1Y (TTM)86.64%
Revenue growth 3Y24.87%
Revenue growth 5Y77.47%
Sales Q2Q%101.76%
Revenue Next Year91.99%
Revenue Next 2Y63.27%
Revenue Next 3Y46.49%
Revenue Next 5Y30.94%
EBIT growth 1Y26.99%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year88.64%
EBIT Next 3Y41.38%
EBIT Next 5Y30.46%
FCF growth 1Y164.19%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y206.97%
OCF growth 3YN/A
OCF growth 5YN/A

XPENG INC - ADR / XPEV FAQ

Can you provide the ChartMill fundamental rating for XPENG INC - ADR?

ChartMill assigns a fundamental rating of 4 / 10 to XPEV.


Can you provide the valuation status for XPENG INC - ADR?

ChartMill assigns a valuation rating of 4 / 10 to XPENG INC - ADR (XPEV). This can be considered as Fairly Valued.


Can you provide the profitability details for XPENG INC - ADR?

XPENG INC - ADR (XPEV) has a profitability rating of 2 / 10.